**
Overview
Conditions Encyclopedia Entry 1777461665, also known as Mucopolysaccharidosis Type II (MPS II), is a rare genetic disorder that affects approximately 1 in 25,000 to 1 in 50,000 individuals worldwide. It is a type of lysosomal storage disease, which occurs when the body is unable to break down and recycle certain mucopolysaccharides (complex carbohydrates). As a result, these substances accumulate in various organs and tissues, leading to progressive damage and a range of debilitating symptoms.
MPS II is caused by a deficiency of the enzyme iduronate-2-sulfatase, which is responsible for breaking down heparan sulfate and dermatan sulfate. The disorder is inherited in an X-linked recessive pattern, meaning that it primarily affects males, who have only one X chromosome. Females can be carriers of the disorder, but they are less likely to develop symptoms due to the presence of a second X chromosome.
History/Background
The first reported case of MPS II dates back to 1963, when a group of researchers described a 6-year-old boy with a rare condition characterized by clouded corneas, skeletal abnormalities, and mental retardation. Since then, numerous studies have been conducted to better understand the underlying causes and mechanisms of the disorder. In the 1970s and 1980s, researchers identified the enzyme deficiency responsible for MPS II and developed diagnostic tests to detect the condition.
Key Information
MPS II is characterized by a range of symptoms, including:
* Clouded corneas and vision problems
* Skeletal abnormalities, such as short stature and joint deformities
* Mental retardation and behavioral problems
* Respiratory problems, including pneumonia and bronchiectasis
* Cardiovascular problems, including heart failure and arrhythmias
The symptoms of MPS II typically become apparent in early childhood, although some individuals may not develop noticeable symptoms until later in life. The disorder is progressive, meaning that it worsens over time, and there is currently no cure. However, various treatments and therapies can help manage the symptoms and improve the quality of life for individuals with MPS II.
Significance
MPS II is a rare but serious condition that affects individuals and families worldwide. Understanding the underlying causes and mechanisms of the disorder has led to the development of diagnostic tests and treatments, which can help improve the lives of those affected. Additionally, research into MPS II has contributed to our understanding of lysosomal storage diseases and the importance of enzyme replacement therapy.
INFOBOX:
- Name: Mucopolysaccharidosis Type II (MPS II)
- Type: Genetic disorder
- Date: 1963 (first reported case)
- Location: Worldwide
- Known For: Rare genetic disorder characterized by lysosomal storage material accumulation
TAGS: Lysosomal storage disease, Mucopolysaccharidosis, MPS II, Iduronate-2-sulfatase, Heparan sulfate, Dermatan sulfate, X-linked recessive, Enzyme replacement therapy, Rare genetic disorder.
